Acetyl Salicylic Acid, <scp>COX</scp>‐2 Inhibitors and Other <scp>NSAIDs</scp> and Breast Cancer Survival in a Finnish Population‐Based Cohort
Post-diagnostic use of ASA is associated with reduced BCa-specific mortality, distinguishing ASA from other NSAIDs. Clinical trials are required to determine the ideal ASA dose, frequency, and duration for treating BCa. Pre-diagnostic use of NSAIDs overall is associated with a slight reduction in BCa mortality without dose dependence. The potential role of pre-diagnostic NSAID use as a prognostic factor in BCa warrants further investigation.
Authors
- Kumar Visvanathan (ORCID: https://orcid.org/0000-0002-1176-5442)
- Otso Arponen (ORCID: https://orcid.org/0000-0002-8541-0126)
- Mika O. Murto (ORCID: https://orcid.org/0000-0001-7922-1444)
- Aino Siltari (ORCID: https://orcid.org/0000-0002-7814-427X)
- Miia Artama (ORCID: https://orcid.org/0000-0002-5969-8007)
- M. Malin (ORCID: https://orcid.org/0009-0008-2155-8480)
- Teemu J. Murtola (ORCID: https://orcid.org/0000-0003-2932-9590)
Institutions
- University of Helsinki (FI)
- Johns Hopkins University (US)
- Tampere University (FI)
- Finnish Institute for Health and Welfare (FI)
- Tampere University Hospital (FI)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1002/cnr2.70271
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00